Advanced Therapies in Europe (ATMPs): What the EMA Is Approving and Why It Matters for Longevity Clinics
The EMA publishes its quarterly ATMP report (Jun–Nov 2025): cell, gene, and tissue therapy. A key regulatory signal for clinics offering stem cells or regenerative therapies.
When the EMA’s Committee for Advanced Therapies (CAT) publishes its quarterly ATMP report, it’s not niche news. It’s a signal of the real state of what’s approved, what’s under review, and what remains experimental in Europe.
The CAT report from December 2025 covers the period June–November 2025 and includes updates on approvals, indication extensions, and regulatory activity statistics.
What ATMPs are (and why a longevity clinic should care)
ATMPs (Advanced Therapy Medicinal Products) are medicines based on:
- Gene therapy (genetic modification)
- Somatic cell therapy (non-genetically modified cells, including stem cells)
- Tissue engineering (tissue repair or regeneration)
The critical point for clinics: if a clinic offers stem cell treatments under the label “regenerative” or “anti-aging,” that therapy may be subject to ATMP regulation in the EU — which means centralized authorization, post-marketing surveillance, and pharmacovigilance.
The context: which ATMPs are already approved in Europe
To understand the regulatory bar, it’s worth looking at the ATMPs that have completed the process. Products like Kymriah (tisagenlecleucel, CAR-T therapy for leukemia and lymphoma) and Zolgensma (onasemnogene abeparvovec, gene therapy for spinal muscular atrophy) went through multi-year, multi-center trials with robust safety and efficacy data. Alofisel (darvadstrocel), an allogeneic stem cell therapy for perianal fistulas in Crohn’s disease, also obtained centralized authorization. Each approval cost hundreds of millions in clinical development.
That is the standard. And it is the standard against which any clinic using the word “stem cell” in its commercial offering is measured.
The risk that many clinics ignore
A gray area persists in the sector:
- Some clinics offer “stem cell therapy” as if it were an aesthetic service, outside the regulatory radar.
- European regulation is clear: if the cell undergoes substantial manipulation or is used for a different function, it’s an ATMP and requires EMA approval.
- Violating this can result in sanctions, closure, or litigation.
The hospital exemption: the gray hole
ATMP regulation includes an alternative pathway known as the hospital exemption (Article 28 of Regulation 1394/2007). It allows a hospital to prepare and administer an unauthorized ATMP to a specific patient under medical prescription and hospital responsibility, without going through centralized EMA authorization.
In practice, this exemption has become an operational gray area. Some centers in Spain and Portugal offer stem cell treatments under this coverage, with varying interpretations of what constitutes “individualized use” versus a systematic commercial program. Oversight depends on national agencies (AEMPS in Spain, Infarmed in Portugal), and the rigor of enforcement varies significantly between countries.
The real enforcement landscape
The reality is that national agencies’ inspection capacity is limited. Enforcement actions tend to be reactive — triggered by reported adverse events or complaints — rather than proactive. This creates an environment where the “more serious” longevity sector is calling for clear regulation not as a threat, but as a competitive advantage over gray-area operators.
What a responsible clinic should do
- Review what it offers and how it labels it.
- Check whether its supplier or protocol is subject to ATMP regulation (or should be).
- If operating in a gray area, seek legal/regulatory counsel before an inspection arrives.
- If it wants to offer real cell therapies: participate in clinical trials as a legitimate and documented pathway.
The longevity industry group led by ArentFox Schiff is working precisely on frameworks that allow serious operators to differentiate themselves. For European clinics, understanding ATMP regulation is not optional: it’s the line between operating legitimately and taking a risk that could end in closure.
Primary source: EMA — CAT Quarterly Highlights (Dec 2025) (Source: EMA, 2025).